Details of the Drug Reposition

General Information of This Drug (ID: DM3R8YL)

Drug Name
Erythropoietin   DM3R8YL
Synonyms NuPIAO; Erythropoietin (second generation, anemia/blood cell mobilization); Erythropoietin (second generation, anemia/blood cell mobilization), 3SBio
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Periventricular leukomalacia DIS152XL N.A. Approved [1]
Traumatic brain injury DISN8K9H NA07.Z Approved [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Kidney failure DISOVQ9P GB6Z Discontinued in Phase 3 [3]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Anemia DISTVL0C 3A00-3A9Z Investigative [4]
------------------------------------------------------------------------------------

References

1 Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia. Exp Neurol. 2011 Aug;230(2):227-39.
2 Microglial polarization in TBI: Signaling pathways and influencing pharmaceuticals. Front Aging Neurosci. 2022 Aug 1;14:901117.
3 Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4921).